SE1650260A1 - Imatinib for use in the treatment of stroke - Google Patents
Imatinib for use in the treatment of stroke Download PDFInfo
- Publication number
- SE1650260A1 SE1650260A1 SE1650260A SE1650260A SE1650260A1 SE 1650260 A1 SE1650260 A1 SE 1650260A1 SE 1650260 A SE1650260 A SE 1650260A SE 1650260 A SE1650260 A SE 1650260A SE 1650260 A1 SE1650260 A1 SE 1650260A1
- Authority
- SE
- Sweden
- Prior art keywords
- imatinib
- day
- dose
- patient
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (24)
1. Imatinib för användning i behandling av stroke, kännetecknat av attnämnda Imatinib ges till en patient i en dos av 650 mg/ dag eller högre underminst 3 dagar i följd, förträdesvis minst 4 dagar i följd, mest föredraget minst 5 dagar i följd.
2. Imatinib för användning säsom definierats i krav 1, varvid nämndaImatinib ges till en patient i en dos av 700 mg/ dag eller högre, företrädesvis 750 mg/ dag eller högre, mer företrädesvis 800 mg / dag eller högre.
3. Imatinib för användning säsom definierats i nägot av kraven 1 eller 2,varvid nämnda Imatinib ges till en patient före, samtidigt som eller efter trombektomi.
4. Imatinib för användning säsom definierats i nägot av kraven 1 till 3,varvid nämnda Imatinib ges till en patient före, samtidigt som eller efter trombolys.
5. Imatinib för användning säsom definierats i nägot av kraven 1 till 4,varvid nämnda Imatinib ges till en patient som behandlas eller har behandlats trombektomi och trombolys.
6. Imatinib för användning säsom definierats i nägot av kraven 4 och 5,varvid nämnda trombolys innefattar administrering av envävnadsplasminogenaktivator (tPA) vald ur gruppen bestäende av alteplase(ACTIVASE®), reteplas (RETEVASE®, RAPILYSIN®) och tenekteplas(TNKase®).
7. Imatinib för användning i behandling av stroke, varvid Imatinib ges tillen patient innan det har bestämts om patienten lider av akut ischemisk stroke eller hemorrhagisk stroke.
8. Imatinib för användning säsom definierats i nägot av kraven 1 till 7,varvid Imatinib ges till en patient med en startdos av 1000 mg/ dag ellerhögre under dag 1 och med en dos i intervallet 650 mg/ dag till 1000 mg / dag under de efterföljande dagarna. 15879SE
9. Imatinib för användning såsom definierats i något av kraven 1 till 8, varvid nämnda Imatinib administreras oralt.
10. Imatinib för användning säsom definierats i nägot av kraven 1 till 8, varvid nämnda Imatinib administreras intravenöst.
11. Imatinib för användning säsom definierats i krav 8, varvid minst en delav nämnda startdos administreras intravenöst och de efterföljande doserna administreras oralt.
Priority Applications (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (sv) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
| PT177603990T PT3423060T (pt) | 2016-02-29 | 2017-02-27 | Imatinib para utilização no tratamento de acidente vascular cerebral |
| HUE17760399A HUE056798T2 (hu) | 2016-02-29 | 2017-02-27 | Imatinib stroke kezelésében való alkalmazásra |
| HRP20211621TT HRP20211621T1 (hr) | 2016-02-29 | 2017-02-27 | Imatinib za uporabu u liječenju moždanog udara |
| US16/080,529 US10953010B2 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| CN201780013732.6A CN108697711A (zh) | 2016-02-29 | 2017-02-27 | 伊马替尼在治疗中风中的用途 |
| RS20211286A RS62465B1 (sr) | 2016-02-29 | 2017-02-27 | Imatinib za upotrebu u lečenju moždanog udara |
| ES17760399T ES2895432T3 (es) | 2016-02-29 | 2017-02-27 | Imatinib para uso en el tratamiento de accidente cerebrovascular |
| EP17760399.0A EP3423060B1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| PL17760399T PL3423060T3 (pl) | 2016-02-29 | 2017-02-27 | Imatynib do stosowania w leczeniu udaru mózgu |
| AU2017227515A AU2017227515B2 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| CN202411509669.3A CN119523986A (zh) | 2016-02-29 | 2017-02-27 | 伊马替尼在治疗中风中的用途 |
| SI201730931T SI3423060T1 (sl) | 2016-02-29 | 2017-02-27 | Imatinib za uporabo pri zdravljenju možganske kapi |
| JP2018545843A JP6914957B2 (ja) | 2016-02-29 | 2017-02-27 | 脳卒中の処置における使用のためのイマチニブ |
| LTEPPCT/SE2017/050183T LT3423060T (lt) | 2016-02-29 | 2017-02-27 | Imatinibas, skirtas naudoti insulto gydymui |
| RU2019122730A RU2739382C1 (ru) | 2016-02-29 | 2017-02-27 | Иматиниб для применения для лечения инсульта |
| PCT/SE2017/050183 WO2017151043A1 (en) | 2016-02-29 | 2017-02-27 | Imatinib for use in the treatment of stroke |
| DK17760399.0T DK3423060T3 (da) | 2016-02-29 | 2017-02-27 | Imatinib til anvendelse til behandling af slagtilfælde |
| US17/186,303 US20210236488A1 (en) | 2016-02-29 | 2021-02-26 | Imatinib for use in the treatment of stroke |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650260A SE539450C2 (sv) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE1650260A1 true SE1650260A1 (sv) | 2017-08-30 |
| SE539450C2 SE539450C2 (sv) | 2017-09-26 |
Family
ID=59744327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1650260A SE539450C2 (sv) | 2016-02-29 | 2016-02-29 | Imatinib for use in the treatment of stroke |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953010B2 (sv) |
| EP (1) | EP3423060B1 (sv) |
| JP (1) | JP6914957B2 (sv) |
| CN (2) | CN119523986A (sv) |
| AU (1) | AU2017227515B2 (sv) |
| DK (1) | DK3423060T3 (sv) |
| ES (1) | ES2895432T3 (sv) |
| HR (1) | HRP20211621T1 (sv) |
| HU (1) | HUE056798T2 (sv) |
| LT (1) | LT3423060T (sv) |
| PL (1) | PL3423060T3 (sv) |
| PT (1) | PT3423060T (sv) |
| RS (1) | RS62465B1 (sv) |
| RU (1) | RU2739382C1 (sv) |
| SE (1) | SE539450C2 (sv) |
| SI (1) | SI3423060T1 (sv) |
| WO (1) | WO2017151043A1 (sv) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
| CN114306342B (zh) * | 2020-09-30 | 2024-06-28 | 江苏先声药业有限公司 | 一种注射用伊马替尼盐的药物组合物及其制备方法 |
| CN118524852A (zh) * | 2021-11-09 | 2024-08-20 | 真和制药有限公司 | 治疗或抑制心血管疾病的方法 |
| EP4311539A1 (en) | 2022-07-29 | 2024-01-31 | Artorange Ltd. | Imatinib formulation for parenteral administration |
| US20250000934A1 (en) | 2023-06-28 | 2025-01-02 | Pharmazz, Inc. | Lyophilized sovateltide-based injectable formulation and method for preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148074A (en) * | 2005-05-10 | 2013-02-28 | Novartis Ag | Pharmaceutical compositions comprising imatinib and a release retardant |
| AU2007240429A1 (en) * | 2006-04-17 | 2007-11-01 | Ludwig Institute For Cancer Research Ltd | Methods and compositions for modulation of blood-neural barrier |
| US7977348B2 (en) * | 2006-04-27 | 2011-07-12 | Sicor Inc. | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α |
| JP2009514988A (ja) * | 2006-10-26 | 2009-04-09 | シコール インコーポレイティド | イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法 |
| US20100136094A1 (en) | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
| SI2411028T1 (sl) * | 2009-03-27 | 2019-09-30 | Moleac Pte Ltd | Terapija za pospeševanje celične rasti |
-
2016
- 2016-02-29 SE SE1650260A patent/SE539450C2/sv not_active IP Right Cessation
-
2017
- 2017-02-27 HR HRP20211621TT patent/HRP20211621T1/hr unknown
- 2017-02-27 CN CN202411509669.3A patent/CN119523986A/zh active Pending
- 2017-02-27 DK DK17760399.0T patent/DK3423060T3/da active
- 2017-02-27 PL PL17760399T patent/PL3423060T3/pl unknown
- 2017-02-27 ES ES17760399T patent/ES2895432T3/es active Active
- 2017-02-27 WO PCT/SE2017/050183 patent/WO2017151043A1/en not_active Ceased
- 2017-02-27 AU AU2017227515A patent/AU2017227515B2/en active Active
- 2017-02-27 SI SI201730931T patent/SI3423060T1/sl unknown
- 2017-02-27 RS RS20211286A patent/RS62465B1/sr unknown
- 2017-02-27 CN CN201780013732.6A patent/CN108697711A/zh active Pending
- 2017-02-27 JP JP2018545843A patent/JP6914957B2/ja active Active
- 2017-02-27 HU HUE17760399A patent/HUE056798T2/hu unknown
- 2017-02-27 US US16/080,529 patent/US10953010B2/en active Active
- 2017-02-27 RU RU2019122730A patent/RU2739382C1/ru active
- 2017-02-27 LT LTEPPCT/SE2017/050183T patent/LT3423060T/lt unknown
- 2017-02-27 PT PT177603990T patent/PT3423060T/pt unknown
- 2017-02-27 EP EP17760399.0A patent/EP3423060B1/en active Active
-
2021
- 2021-02-26 US US17/186,303 patent/US20210236488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUE056798T2 (hu) | 2022-03-28 |
| EP3423060B1 (en) | 2021-07-21 |
| PL3423060T3 (pl) | 2022-01-10 |
| EP3423060A1 (en) | 2019-01-09 |
| JP2019507165A (ja) | 2019-03-14 |
| EP3423060A4 (en) | 2020-01-01 |
| AU2017227515B2 (en) | 2022-03-24 |
| CN119523986A (zh) | 2025-02-28 |
| RU2739382C1 (ru) | 2020-12-23 |
| US20210236488A1 (en) | 2021-08-05 |
| HRP20211621T1 (hr) | 2022-02-04 |
| PT3423060T (pt) | 2021-10-20 |
| US20190030030A1 (en) | 2019-01-31 |
| CN108697711A (zh) | 2018-10-23 |
| ES2895432T3 (es) | 2022-02-21 |
| RS62465B1 (sr) | 2021-11-30 |
| US10953010B2 (en) | 2021-03-23 |
| DK3423060T3 (da) | 2021-10-25 |
| WO2017151043A1 (en) | 2017-09-08 |
| SE539450C2 (sv) | 2017-09-26 |
| SI3423060T1 (sl) | 2021-11-30 |
| AU2017227515A1 (en) | 2018-08-30 |
| LT3423060T (lt) | 2021-11-10 |
| JP6914957B2 (ja) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210236488A1 (en) | Imatinib for use in the treatment of stroke | |
| EA032515B1 (ru) | Лечение или профилактика сердечно-сосудистых явлений с использованием колхицина | |
| CA3107624C (en) | Composition for eradicating helicobacter pylori | |
| KR20150135339A (ko) | 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도 | |
| KR20240162094A (ko) | 미르다메티닙 치료 | |
| JP2022173299A (ja) | 中枢神経系（ｃｎｓ）がんを治療するためのプロテアソーム阻害剤の利用 | |
| JP2025502266A (ja) | 有害な薬物相互作用及び影響を回避するためにウパダシチニブを投与する方法 | |
| KR20230106644A (ko) | S1p1 수용체와 관련된 상태를 치료하는 방법 | |
| JP6042886B2 (ja) | 早漏症治療用の薬学組成物 | |
| RU2821032C1 (ru) | Способы лечения заболеваний, связанных с рецептором s1p1 | |
| KR20190134825A (ko) | 수축력 저하 수반성 배뇨근 과활동 개선제 | |
| RU2845317C1 (ru) | Способ лечения постковидного синдрома | |
| RU2729425C2 (ru) | Дозы панобиностата для множественной миеломы | |
| Giaquinto | Side effects of drugs that affect blood coagulation, fibrinolysis and hemostasis | |
| CN115120606A (zh) | 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 | |
| TW202342049A (zh) | 治療患有腦損傷的患者的方法以及增加患有腦損傷的患者的擴展版格拉斯哥結局量表的值的方法 | |
| US20250295648A1 (en) | Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol | |
| Alkanat et al. | Dermatologic Reactions Following COVID-19 Vaccination: A Case Series. | |
| Naeem et al. | Posterior Fossa Hemorrhage Following the Use of Low-Molecular-Weight Heparin: Lessons Learned and Recommendations for the Treatment and Prophylaxis of Postoperative Venous Thromboembolism | |
| TW202400145A (zh) | 治療ｓ１ｐ受體相關病況之方法 | |
| US20180243247A1 (en) | Drug combinations for cerebrovascular disease | |
| US20240239840A1 (en) | method for the treatment of pain and a medicinal product for administration during pain | |
| HK40073112A (en) | Methods of treating, reducing the incidence of, and/or preventing ischemic events | |
| CN120241740A (zh) | Ikk激酶抑制剂在制备治疗脑卒中药物中的应用 | |
| CN118891046A (zh) | 施用乌帕替尼以避免不良药物相互作用和反应的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |